Short Interest in Exicure, Inc. (NASDAQ:XCUR) Declines By 19.8%

Exicure, Inc. (NASDAQ:XCUR - Get Free Report) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 27,500 shares, a decline of 19.8% from the March 31st total of 34,300 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average daily volume of 41,100 shares, the short-interest ratio is presently 0.7 days.

Exicure Stock Performance

Shares of XCUR remained flat at $10.73 during mid-day trading on Monday. The stock had a trading volume of 7,255 shares, compared to its average volume of 571,806. The stock has a 50-day simple moving average of $11.65 and a 200-day simple moving average of $11.60. The stock has a market cap of $67.79 million, a P/E ratio of -5.18 and a beta of 3.86. Exicure has a twelve month low of $1.44 and a twelve month high of $36.00.

Exicure (NASDAQ:XCUR - Get Free Report) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.

Institutional Investors Weigh In On Exicure

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC acquired a new stake in Exicure, Inc. (NASDAQ:XCUR - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,645 shares of the company's stock, valued at approximately $173,000. Geode Capital Management LLC owned 0.48% of Exicure at the end of the most recent quarter. Institutional investors own 42.82% of the company's stock.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.